Oncolytic adenoviruses are being investigated as potential anti-cancer agents. Selective lytic replication in cancer cells is essential for an effective and safe treatment. In this study, we compared 11 oncolytic adenoviruses in relevant cell cultures to assess their use for treating oral cancer and pre-cancerous lesions. We determined the cytotoxicity of oncolytic adenovirus infection and calculated selectivity indices for cytotoxicity to cancer cells compared with normal oral keratinocytes and fibroblasts. Keratinocytes were very sensitive to wild-type adenovirus serotype 5 (Ad5); 1-to 3-log more than head and neck squamous cell carcinoma (HNSCC) cells. The potencies of oncolytic adenoviruses to kill HNSCC cells within 7 days after infection ranged from approximately 10 times less potent to approximately 10 times more potent than Ad5. The selectivity indices determined on fibroblasts and keratinocytes differed markedly. Two oncolytic adenoviruses were more selective than Ad5 for HNSCC cells compared with fibroblasts; and five viruses showed selective replication on HNSCC cells compared with keratinocytes. Overall, CRAd-S.RGD with E1A driven by the survivin promoter and an infectivity-enhancing capsid modification showed the most favourable cytotoxicity pattern; being very potent in killing HNSCC cells, only slightly less effective than Ad5 in killing pre-neoplastic keratinocytes and the least toxic to normal keratinocytes.
Oncolytic viruses are being developed as new agents to treat cancer. 1, 2 Oncolytic viruses are considered valuable additions to the arsenal of therapeutic agents to combat cancer. They destroy tumours by preferential lytic replication in cancer cells through mechanisms partly distinct from those of standard cancer therapies such as cytotoxic drugs and irradiation. Moreover, selective production of progeny virus in tumours increases the dose in situ, which might yield a higher therapeutic index. Currently, oncolytic viruses derived from adenovirus are the most extensively studied in clinical trials. 1, 2 Many different oncolytic adenoviruses have been engineered, mainly following two molecular approaches. 3, 4 In the first approach, production of early adenovirus proteins essential for viral replication is promoted by a tumour-selective promoter, inhibiting replication in nonmalignant cells. In the second, adenovirus genes are deleted or mutated, rendering viral replication dependent on complementing alterations in cancer cells. Although each of these manipulations of the adenovirus genome provides a level of cancer cell specificity, none was reported to abort replication in non-malignant cells completely. Therefore, oncolytic adenoviruses were made that incorporate multiple modifications, and in general such viruses showed a more strict tumourselective replication. [5] [6] [7] [8] [9] Clinical experience with oncolytic adenoviruses has shown their safety, with some evidence of efficacy. 1 This has fuelled studies aimed at empowering the cancer cell killing potency of oncolytic adenoviruses, without compromising their selectivity. To this end, adenoviruses were armed with therapeutic transgenes. 10 Among these were genes encoding proteins that promote cancer cell lysis and efficient spread of progeny virus, including a dominant-negative mutant of Ik-B, tumour suppressor p53 and fusogenic membrane glycoproteins. [11] [12] [13] [14] The impact of the aforementioned selectivity-and efficacyenhancing adenovirus genome modifications depends on the biology of the host cancer cell. It can thus be anticipated that different types of cancer each demand a different oncolytic adenovirus offering the highest therapeutic index. In addition, safety of the virus on normal cells may depend on tissue architecture and administration route. Therefore, to identify the most useful oncolytic adenovirus for a particular cancer indication, direct comparisons in relevant model systems need to be made.
Head and neck squamous cell carcinoma (HNSCC) originates in the mucosal linings of the upper aero-digestive tract, and is diagnosed worldwide approximately 500 000 times each year. Initial-stage tumours are usually treated by surgery or radiation, whereas advanced-stage tumours are treated by a combination of surgery and postoperative radiotherapy, chemo-radiation or bio-chemoradiation. Despite advances in therapy, the long-term survival rate of HNSCC patients has increased only moderately over the past decades. An important clinical problem is the frequent development of local relapse, clinically assigned as local recurrence or second primary tumour in the same or adjacent anatomical area, depending on the distance from the index tumour or the time interval. Most HNSCCs, particularly those in the oral cavity and oropharynx, emerge in pre-neoplastic fields consisting of genetically altered cells in which multiple mutations accumulate as a result of chronic exposure to carcinogens. 15 These pre-neoplastic fields can extend up to many centimetres in diameter and are clinically not visible in approximately 80% of cases. 15 Because of their dimensions and invisibility, pre-neoplastic fields are often left behind in part when the tumour is excised. This puts patients with HNSCC at a high risk of developing local relapse (10-25%) arising from the same pre-neoplastic field as the first primary tumour. 16 Thus, new treatments aimed at eradication of these pre-cancerous fields are desperately needed to prevent local relapses in treated HNSCC patients. Eradicating pre-neoplastic fields is also of relevance to prevent malignant transformation of visible pre-cancerous lesions, such as leukoplakias and erythroplakias. These secondary and tertiary prevention strategies are of interest for the sporadic patient population, but in particular for those who are genetically predisposed and at a very high risk for developing squamous cancers, such as patients with Fanconi anemia (FA). FA is an inherited disease characterized by bone marrow failure, congenital abnormalities and cancer predisposition, particularly acute myeloid leukaemia and HNSCC. Since the introduction of bone marrow transplantation for FA patients allowing treatment of the most lifethreatening complications, increasing numbers of FA patients survive longer and develop HNSCC. The tumours in these patients are difficult to treat, because FA patients do not sustain radiotherapy and chemotherapy, leaving prevention, screening and surgery of the tumours as only options for clinical management. Precancerous fields are often seen in these patients and a secondary prevention strategy of these lesions is urgently awaited.
Oncolytic adenoviruses appear very useful to treat HNSCC. Several clinical trials with the oncolytic adenovirus ONYX-015 have been performed in HNSCC patients [17] [18] [19] and the very similar virus H101 is already registered as an HNSCC medicine in China. 20 In addition, oncolytic adenoviruses could potentially also be used to eradicate pre-neoplastic lesions, because preneoplastic cells carry some of the genetic aberrations found in cancer cells that are exploited to design oncolytic adenoviruses. Moreover, the confinement of HNSCC and its pre-neoplastic fields to the oral mucosa, allowing exposure to virus through topical administration, makes this a particularly attractive indication for treatment with oncolytic adenovirus. Indeed, the feasibility of administering ONYX-015 to pre-neoplastic oral lesions by rinsing the oral cavity with a virus suspension is already shown in a clinical trial, 21 but the reported efficacy leaves much to be desired.
In this study, we set out to evaluate a panel of oncolytic adenoviruses on cell cultures relevant for treating oral and oropharyngeal cancer and their precancerous fields. We included five human HNSCC cell lines, two of which were derived from FA patients; a preneoplastic cell culture derived from the resection margin of an excised HNSCC specimen and the two main cellular constituents of the healthy oral mucosa, that is, primary oral keratinocytes that form the squamous stratified epithelium and fibroblasts from the underlying connective tissue. The squamous stratified epithelium consists of different layers. Keratinocytes in the basal and suprabasal layers divide, move upwards to more superficial layers, differentiate and lose replication potential. Hence, topical application of adenovirus by mouthwash brings in particular differentiated superficial keratinocytes in contact with virus. To culture keratinocytes resembling this differentiated cell type, we induced primary oral keratinocytes to differentiate by addition of calcium to the culture medium. 22 Keratinocytes cultured for 7 days in the presence of calcium show morphological changes (Supplementary Figure 1A) and down-regulation of K984 antigen expression and upregulation of K928 antigen expression (Supplementary Figure 1C ; Supplementary Table 1) typical for differentiating keratinocytes in the suprabasal and superficial layers of the oral mucosa (Supplementary Figure 1B) .
First, we investigated inherent susceptibility of the different normal and malignant cell types to human adenovirus serotype 5 (Ad5) infection and lytic replication. Infection efficiency was studied using AdCMVLuc, 23 a replication-defective Ad5 vector expressing firefly luciferase. Cells were subjected to AdCMV-Luc at various multiplicities of infection and luciferase activity was measured the next day. All cell cultures showed a linear relation between multiplicity of infection and luciferase activity in the range of 10-1000 IU per cell. Figure 1a shows the comparison at 100 IU per cell. AdCMV-Luc did not show preference for infection of malignant or non-malignant cells derived from the oral epithelium. The five HNSCC cell lines showed highly variable susceptibility to infection, with UM-SCC-22A being 70-fold more resistant than VU1365. In addition, cells were analysed by fluorescence-activated cell sorting for expression of the primary and secondary Ad5 receptors CAR and av integrins (Supplementary Table 1 ). This showed that CAR was virtually absent on fibroblasts and expressed at variable levels on the other cell types, whereas integrins were expressed on all cell types. Neither CAR expression, nor integrin expression levels correlated with infection efficiency (Spearman's rank correlation test: CAR, r ¼ 0.21, P ¼ 0.66; integrins, r ¼ 0.11, P ¼ 0.84).
Next, we compared the inherent susceptibility of the cells to Ad5-induced cell kill. To this end, we infected cells with an Ad5 dilution titration and measured cell viability 7 days later. Replication-defective AdCMV-Luc was taken along as control for replication-independent adenovirus particle toxicity. The inverse of the virus dose required to decrease cell viability by 50% (1/LD 50 ) was used as a measure for cytotoxic activity. Figure 1b shows that of all cell types tested, keratinocytes were the most sensitive to Ad5-induced cell kill and fibroblasts were the HNSCC cell lines UM-SCC-11B, UM-SCC-14C and UM-SCC-22A were derived from sporadic tumours and cultured in DMEM with 5% FCS (Gibco Invitrogen, Breda, the Netherlands), 50 U ml À1 penicillin, 50 mg ml À1 streptomycin and 2 mM L-glutamine (all from BioWhittaker, Verviers, Belgium). HNSCC cell lines VU1131 and VU1365 were derived from tumours of Fanconi anemia patients defective in FANCC and FANCA, respectively; 40 and were cultured in EMEM (Gibco Invitrogen) with the same additives. Primary keratinocytes and fibroblasts were obtained from oral mucosa of patients who underwent uvulopalatopharyngoplasty. To sterilize the specimen, we stored the tissue for 3 days at 4 1C in KGM-SFM (Gibco Invitrogen), with 1% FBS, 50 U ml À1 penicillin, 50 mg ml À1 streptomycin, 10 mg ml À1 gentamicin sulphate (BioWhittaker) and 2.5 mg ml À1 amphotericin B (Gibco Invitrogen). Next, the tissue was put in a Petri dish on a sterile gaze with the stratified epithelium facing upwards. Dispase II solution (240 U per 100 ml; Roche Diagnostics, Almere, the Netherlands) was added until the gaze was completely soaked and the tissue was incubated at 4 1C for 16 h followed by 10 min at 37 1C before the epithelium and underlying connective tissue were separated. The two layers were washed three times in PBS and put in trypsin/EDTA (BioWhittaker) for 10 min at 37 1C with shaking to isolate keratinocytes and fibroblasts. Keratinocytes were grown in KGM-SFM supplemented with 50 mg ml À1 BPE (Gibco Invitrogen), 5 ng ml À1 rEGF (Gibco Invitrogen), 0.5 mg ml À1 amphotericin B, 5 mg ml À1 Gentamicin sulphate and 0.1% (w/v) BSA. Fibroblasts were grown in the same medium as HNSCC cells with FCS concentration increased to 10%. (a) Adenovirus infection efficiency was assessed by measuring luciferase expression in cells transduced with AdCMV-Luc. Cells were seeded in 96-well plates at 2500 cells per well and subjected to AdCMV-Luc at 100 IU per cell in triplicate the next day, except for differentiated keratinocytes that were cultured for 7 days in medium containing 1.8 mM calcium before virus was added. Firefly luciferase activity in relative light units (RLU) was measured using the luciferase chemiluminescent assay system (Promega, Madison, WI, USA) and a Lumat LB 9507 luminometer (EG&G Berthold, Bad Wildbad Germany) 24 h after infection. (b) Cytotoxic activity of wild-type adenovirus. Cells were seeded as above and AdCMV-Luc or Ad5 was added the following day in a twofold dilution titration over the range of 1000-0.00012 IU per cell in triplicate. Cell viability was measured after 7 days. To this end, the culture medium was replaced with WST-1 reagent (Roche Diagnostics, Mannheim, Germany) diluted 10-times in medium. Cells were incubated at 37 1C for 2-4 h before measuring A 450 on a Bio-Rad (Hercules, CA, USA) model 550 microplate reader to reach values of 2.0-2.5 in uninfected controls. Sigmoidal dose-response curves were created and LD 50 values were calculated using GraphPad Prism version 4.0 software (GraphPad Software, San Diego, CA, USA). Three independent experiments were performed. Cytotoxic activities are expressed as median inverse LD 50 values± median absolute deviations. * Cytotoxicity of the AdCMV-Luc control is overestimated, because in one or more experiments the LD 50 was not reached.
Oncolytic adenoviruses for oral cancer treatment HJT van Zeeburg et al correlation test: r ¼ 0.71, P ¼ 0.09), suggesting that Ad5 cytotoxicity on the tested cells could be partly dependent on infection efficiency, but that other intrinsic cellular properties seem to be important as well. Notably, none of the HNSCC cell lines was as sensitive to Ad5 as were keratinocytes. This underscores the importance of introducing tumour-selective modifications in the adenovirus genome, in particular to reduce lytic replication in keratinocytes. In the context of treating oral cancer or pre-neoplastic lesions by mouthwash, protecting fibroblasts against the virus seems less important, as these cells are likely to be less accessible and appear relatively resistant to Ad5 cytotoxicity. Notably, we do not know whether this also holds true for fibroblasts in submucosal fibrosis that is frequently observed in subjects with the habit of chewing betel nuts. These fibroblasts do not behave normally and might be more susceptible for the effects of adenovirus infection.
To identify a most useful oncolytic adenovirus for treating oral cancer or dysplasia, we measured the HNSCC cell killing potency of 11 oncolytic adenoviruses comprising six modifications providing tumour selectivity and three modifications described to affect killing potency. The characteristics of the oncolytic adenoviruses used are shown in Table 1 . Modifications conferring tumour-selective replication included deletion of the p300/CBP-binding motif in the N-terminal region of E1A, 7,24 deletion of a pRB-binding motif in the E1A-CR2 region, 25, 26 deletion of the entire E1B55K gene 27 or abrogation of the p53 binding site in E1B55K by single amino-acid R240A substitution, 28 and regulation of E1A expression by two tumour-selective promoters, that is, the survivin promoter 29 and the CXCR4 promoter. 30 Modifications that affect oncolytic potency include presence or absence of the adenovirus E3 region, 31, 32 expression of tumour suppressor p53 13, 14 and enhancement of infectivity by inserting a cyclic RGD motif in the fibre capsid protein. 33 Three independent experiments to determine the LD 50 were performed in triplicate for each virus on each cell type. Figure 2a shows, by way of example, results of Ad5 and three oncolytic viruses in one of the experiments on VU1131 cells. Because 27 E1B55K(R240A), point mutation in the E1B-55kD gene resulting in a single R240A amino-acid substitution that abrogates E1B-55kD binding to tumour suppressor protein p53. 28 DE3B, deletion in the E3B region that removes the E3-10.4K, 14.5K and 14.7K genes. RGD4C, insertion of sequence encoding a cyclic RGD motif in the HI loop of the fibre protein that enhances adenovirus infectivity through binding to av integrins. TP53, gene encoding tumour suppressor protein p53. The oncolytic adenoviruses constructed in this study were made using the AdEasy system. 42 Shuttle vector pScs/PA/S carrying the survivin promoter to drive wild-type E1A was described before.
29 pXC1-D24 25 was used as starting point to construct viruses with the D24 mutation. The E1B55K(R240A) mutation was introduced by PCR using pXC1-D24 as template. First, two overlapping segments were amplified with primers E1B-F (5 0 -TGAATCTGGGTCACCAGGCGC-3 0 ) and R240A-R (5 0 -GGGGCCAGTAAACGCTACATTCATAATAAC-3 0 ); and R240A-F (5 0 -GTTATTATGAATGTAGCGTTTACTGGCCCC-3 0 ) and E1B-R (5 0 -CGGTCACATCCAGCATCACAGGC-3 0 ), respectively. Next, amplification products were mixed and amplified using primers E1B-F and E1B-R. The 1.5 kb product of this reaction, including an AG4GC substitution (underlined in the primers) encoding E1B-55K amino acid 240 Arg4Ala, was digested with KpnI and BglII and ligated into KpnI/ BglII-digested pXC1-D24 to create pXC1-D24.55K(R240A). Next, the E1 regions of pXC1-D24 and pXC1-D24.55K(R240A) were introduced after digestion with BamHI and XmnI into XbaI/XhoI-linearized pShuttle-CMV 42 by homologous recombination in E. coli BJ5183 cells, yielding pShuttle-D24 and pShuttle-D24.55K(R240A), respectively. The DN deletion was introduced into pShuttle-D24 by PCR. For this, the E1A regions upstream of the sequences encoding amino acid 4 and downstream of the sequences encoding amino acid 25 were first amplified separately using primer sets E1A-F (5 0 -CCCAATATTTGTCTAGGGCC-3 0 ) and DN4-R (5 0 -CAGTACCTCATGTCTCATTTTCAGTCCCG-3 0 ); and DN25-F (5 0 -ATGAGACATGAGGTACTGGCTGATAATCT-3 0 ) and E1A-R (5 0 -CCCATCGATCACCTCCG-3 0 ), respectively. The 5 0 ends of primers DN4-R and DN25-F comprise 9 nucleotides downstream of amino acid 25 and upstream of amino acid 4, respectively (underlined). Next, the two amplification products carrying an 18-nucleotide complementary sequence were mixed and amplified using primers E1A-F and E1A-R. The product of this reaction was cut at the SspI and ClaI sites present in the primers (italics) and cloned into SspI/ClaI-digested pShuttle-D24 to yield pShuttle-DND24. Construct pShuttle-DND24.55K(R240A) comprising all three mutations DN, D24 and E1B55K(R240A) was created by exchanging the 1465 bp XbaI-HindIII fragment of pShuttle-DND24 with the corresponding fragment from pShuttle-D24.55K(R240A). All mutations were confirmed by sequencing. Shuttle vectors were linearized with PmeI and recombined with pAdEasy-1 42 in E. coli BJ5183 cells to yield full-length oncolytic adenovirus genome carrying plasmids. PacI-linearized plasmids were transfected into E1-complementing 293 or 911 cells. To minimize the chance for recombination with wild-type E1 sequences, we lysed cells after a few days and viruses were propagated further on A549 cells. Mutations were confirmed on the final preparations and infectious unit (IU) titres were determined using the Adeno-X Rapid Titer Kit (BD Biosciences, Alphen aan de Rijn, the Netherlands) according to the manufacturer's protocol adapted to a 96-well plate format.
Oncolytic adenoviruses for oral cancer treatment HJT van Zeeburg et al different cell lines show highly variable inherent sensitivity to adenovirus-induced cell death (see Figure 1b) , we normalized data by the LD 50 of Ad5. This normalization also corrects for inter-experimental variation. Supplementary Figure 2 shows the normalized oncolytic potencies of all test viruses on the five HNSCC cell lines; Figure 2b shows the mean results of each virus on the complete set of HNSCC cell lines. The AdD24-type viruses were quite consistent in their cytotoxicity against HNSCC cells. In contrast, viruses with multiple E1 modifications or with tumour-selective promoters were much more variable in their potency against individual HNSCC cell lines. Mean oncolytic potencies differed from approximately 10-times less potent than Ad5 to approximately 10-times more potent. Of note, these differences that became evident after only 7 days of culture are expected to amplify upon extended virus propagation. Consistent with findings by others, 8, 26, 34, 35 ONYX-015 was attenuated compared with Ad5, whereas AdD24 was similarly effective as Ad5. In our experiments, the latter was not influenced by the presence or absence of the E3 region, whereas insertion of an RGD motif or a p53 expression cassette yielded a small potency enhancement. Previous studies reported more profound effects in other cancer cell types. 14, 31, 33, 36 Not unexpectedly, introduction of second or third modifications in the E1 region attenuated the killing potency of the virus. In contrast, CRAd-S.RGD and CRAd-CXCR4.RGD were on average more potent against HNSCC cells than Ad5, but with considerable differences between cell lines. These viruses showed a particularly strong cytotoxicity on VU1131 cells. The presence of an RGD motif or E3 region seems essential for this effect, as AdSurE1, which lacks E3 and RGD but is otherwise identical to CRAd-S.RGD, was rather ineffective against VU1131 cells. This was surprising, because in the context of AdD24-type viruses the effect of RGD and E3 was minimal (compare Ad5-D24.RGD with AdD24). Figure 2c shows the selectivity indices of the viruses, calculated from their mean relative cytotoxicities on HNSCC cells versus normal cells. Keratinocyte proliferation was reduced, but not entirely blocked, by addition of calcium; fibroblast proliferation was not inhibited. Most oncolytic adenoviruses did not show appreciable selectivity for HNSCC cells compared with fibroblasts. Their potency attenuation or enhancement compared with Ad5 was similar on HNSCC cells and fibroblasts, yielding selectivity indices around 1. The exceptions were AdD24-p53 and CRAd-S.RGD, which were approximately 10-times more selective than Ad5 on HNSCC cells versus fibroblasts. In contrast, large differences over 4 orders of magnitude were observed in the selectivity of oncolytic viruses for HNSCC cells Oncolytic adenoviruses for oral cancer treatment HJT van Zeeburg et al compared with keratinocytes. AdD24-type viruses, except Ad5-D24.RGD, were at least as toxic to keratinocytes as to HNSCC cells. Surprisingly, several of these viruses were even more toxic to keratinocytes than to HNSCC cells. AdDND24.55K(R240A), which incorporates three E1 modifications intended to provide oncolytic selectivity, yielded a selectivity index similar to that of AdD24 and 50-fold lower than that of Ad5. Adding more E1 modifications to the D24-deletion thus did not improve oncolytic adenovirus selectivity. In contrast, Ad5-D24.RGD, ONYX-015 and the three promoter-driven viruses showed selectivity indices ranging from 4 for Ad5-D24.RGD to 171 for CRAd-S.RGD. Hence, RGD modification, E1B55K gene deletion and tumour-selective E1A expression contributed to selective cytotoxicity on HNSCC cells compared with keratinocytes.
Finally, we tested ONYX-015, AdD24-p53 and the two Survivin promoter-driven viruses in comparison with wild-type Ad5 on M3 cells derived from the resection margin of an excised head and neck tumour. M3 cells exhibit continuous growth in calcium-free keratinocyte growth medium and show loss of heterozygosity at chromosomal locations 3p and 9p, consistent with a preneoplastic state (to be published elsewhere). Figure 3 shows that Ad5 killed M3 cells growing in calcium-free medium with a 1/LD 50 of 0.34 and M3 cells with reduced growth in calcium-containing medium with a 1/LD 50 of 0.08. The sensitivity of M3 to Ad5 was within the range observed for HNSCC cell lines; and well below the sensitivity of normal keratinocytes (see Figure 1a) . Of the four oncolytic adenoviruses tested, only AdD24-p53 was at least as potent as Ad5 in killing growing M3 cells. The other viruses were 3-to 7-fold attenuated. Arresting M3 growth reduced the killing potency of most viruses including Ad5. This is consistent with the general requirement of S-phase progression for effective adenovirus replication. AdD24-p53 showed the strongest attenuation by cell-cycle suppression. The exception was ONYX-015, which killed M3 cells with similar efficiency in the presence or absence of calcium. This was remarkable, because it has been reported that replication of E1B55K mutant adenovirus is restricted by the cell cycle. 37 Our observation suggests that at least this restriction does not substantially affect induction of cell death in M3 cells.
In summary, we have tested a large panel of oncolytic adenoviruses for efficacy against HNSCC cells and preneoplastic cells versus toxicity on differentiated keratinocytes and fibroblasts. To enable extrapolation of our findings to clinical data, we included ONYX-015 that has been tested for HNSCC tumour treatment and for eradication of pre-neoplastic fields by oral rinse procedure. Normal keratinocytes appeared much more sensitive to adenovirus infection than HNSCC cells, pre-neoplastic oral keratinocytes and primary fibroblasts. This extends a previous observation made using in vitro engineered oral epithelia. In that study, epithelia prepared using normal keratinocytes were more sensitive to exposure to Ad5 than those prepared using p53 mutant, p16-deficient cells derived from a severe dysplasia. 38 Surprisingly, most AdD24-type viruses were more toxic to keratinocytes than Ad5, whereas they were similarly or less toxic to fibroblasts. Our observation that selectivity indices determined on fibroblasts and keratinocytes differed markedly underscores the importance of evaluating the safety of oncolytic viruses on normal cells relevant for the intended clinical application. For topical application to the oral mucosa we consider testing the safety on keratinocytes most important. In this context, five viruses showed a better efficacy/safety profile than wild-type Ad5. Of these, CRAd-S.RGD appears a particularly promising lead for development of an oncolytic adenovirus oral rinse treatment, being eightfold more potent against HNSCC cells, only threefold less potent against pre-neoplastic keratinocytes cultured from the oral mucosa and approximately 2-log more selective towards oral keratinocytes than Ad5. However, as a consequence of the very high intrinsic susceptibility of differentiated oral keratinocytes to adenovirus replication, even CRAd-S.RGD with 2-log improved selectivity would be expected to cause considerable toxicity to the normal mucosa. Therefore, it seems remarkable that topical application of ONYX-015 to the oral mucosa has shown a beneficial effect on dysplasias without apparent toxicity. 21 Perhaps the explanation could be sought in the specific tissue architecture of the normal oral mucosa. A previous study reported that CAR expression is absent on superficial cells of the oral mucosa. 39 We found reduced expression of CAR and integrins on superficial mucosa cells (Supplementary Figure 3) . Decreased receptor expression could thus render the differentiating oral mucosa relatively resistant to topical adenovirus infection; perhaps even to infectivity-enhanced viruses with the RGD modification. The in vitro experimental model applied in our study does not address this tissue architecture. Our findings suggest that an undamaged mucosal layer, preventing uptake in normal keratinocytes, might be critical to prevent toxicity problems when applying current generation oncolytic adenoviruses using an oral rinse.
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